Wasatch Advisors holds 5.27M Certara shares (NASDAQ: CERT)
Wasatch Advisors has filed an amended Schedule 13G/A, disclosing beneficial ownership of 5,272,166 shares of Certara Inc., which represents 3.3% of the outstanding common stock. The filing, signed by CEO Mike Yeates on April 6, 2026, indicates that Wasatch Advisors holds sole voting power over 3,598,349 shares and sole dispositive power over all 5,272,166 shares. This passive investment is below the 5% threshold that would require a different disclosure classification.
Wasatch Advisors reports 5.27M shares in Certara (NASDAQ: CERT) Amendment No.3
Wasatch Advisors reported an amended passive investment disclosure (Schedule 13G/A, Amendment No. 3) for Certara Inc. (NASDAQ: CERT). The filing indicates that Wasatch Advisors beneficially owns 5,272,166 shares of Certara common stock, representing 3.3% of the class. They hold sole voting power over 3,598,349 shares and sole dispositive power over all 5,272,166 shares, with the filing signed on April 6, 2026.
CERT SEC Filings - Certara, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Certara, Inc. (CERT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It leverages AI-powered summaries, impact scoring, and sentiment analysis to help investors quickly understand key information from these documents. The page also features real-time updates from EDGAR, ensuring prompt access to the latest filings and disclosures.
CERT PE Ratio & Valuation, Is CERT Overvalued
Certara Inc (CERT) is currently considered undervalued based on its forward PE ratio of 12.67 compared to its five-year average of 42.57. The fair price for CERT is estimated to be between $5.72 and $25.02, making its current price of $5.41 undervalued by 5.42%. While its P/S ratio is above the competitor average, its robust revenue growth might not sustain this premium.
[ARS] Certara, Inc. SEC Filing
This article announces an SEC filing of type ARS by Certara, Inc. (CERT) on April 3, 2026, indicating a low impact and neutral sentiment. The filing is available as a PDF document on SEC EDGAR. The article also provides a brief overview of Certara, including its market capitalization, recent news, and latest SEC filings.
Certara (CERT) executive exercises 10,849 RSUs, uses 2,642 shares for tax withholding
Certara, Inc. executive Adrian McKemey exercised 10,849 restricted stock units (RSUs) on April 1, 2026. In connection with this vesting, 2,642 shares were withheld for tax obligations at a value of $5.70 per share, which is an exempt non-market transaction under Rule 16b-3. After these transactions, McKemey directly holds 8,207 common shares and has 21,698 unvested RSUs remaining.
[Form 4] Certara, Inc. Insider Trading Activity
Certara, Inc.'s SVP and General Counsel, Daniel Corcoran, exercised 10,849 restricted stock units (RSUs) on April 1, 2026, as part of his equity-based compensation. Of these, 5,751 shares were withheld at $5.70 each to cover tax obligations. After the transaction, Corcoran directly holds 21,319 common shares, with remaining RSUs scheduled to vest on April 1, 2027, and April 1, 2028.
Certara (CERT) CFO adds 50,605 shares from RSU and PSU vesting plus grant
Certara, Inc. CFO John E. Gallagher reported significant equity transactions on April 1, 2026, stemming from the vesting of restricted stock units (RSUs) and performance stock units (PSUs), along with a new share grant. He acquired a total of 50,605 common shares through vesting and received an additional 23,346 shares as a grant. Following these transactions and the disposition of 25,108 shares for tax withholding, Gallagher directly owns 95,371 shares of Certara common stock.
Certara (CERT) HR chief nets 11,883 shares after RSU vesting and tax withholding
Certara, Inc.'s Chief Human Resources Officer, Rona Anhalt, acquired 11,883 shares after exercising 9,764 restricted stock units (RSUs) and settling tax obligations. This transaction, revealed in a Form 4 filing, involved 3,062 shares being withheld for taxes. The vesting represents one-third of an RSU grant from May 20, 2025, with the remaining two-thirds scheduled to vest in 2027 and 2028.
Certara Inc. (CERT) Stock Price | Live Quotes & Charts | NASDAQ
This article provides live stock quotes and charts for Certara Inc. (CERT), showing a current price of $5.41 with a 1.64% decrease. It notes that there are no recent analyst ratings or earnings information available for the company. The page also features promotional content for trading conferences and a platform called StocksToTrade.
Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of "Hold" by Analysts
Certara, Inc. (NASDAQ:CERT) has received a consensus "Hold" rating from fourteen analysts, with an average 12-month price target of $11.10. The company recently reported Q4 EPS of $0.09, missing estimates, but revenue was largely in line, showing a 3.2% year-over-year increase. Institutional investors hold a significant portion of the stock, with several increasing their stakes.
Certara Announces Upcoming Board and Audit Committee Change
Certara announced that board member Cynthia Collins will resign as a Class II director and member of the Audit Committee, effective May 14, 2026, coinciding with the company’s annual meeting. The company stated that her departure is not due to any disagreements with Certara's operations. Investors will likely watch how Certara addresses this vacancy, as audit committee composition is crucial for financial reporting and regulatory compliance.
Certara Announces Upcoming Board and Audit Committee Change
Certara (CERT) announced that board member Cynthia Collins will resign from her Class II directorship and Audit Committee role, effective May 14, 2026, coinciding with the company’s annual meeting of stockholders. The company stated that her departure is not due to any disagreements regarding Certara's operations, policies, or practices. This change will require Certara to address the vacancy, potentially by realigning board responsibilities or appointing a new director with financial oversight expertise.
Cynthia Collins to Resign from Certara Board, Effective May 14, 2026
Cynthia Collins will resign from her position as a Class II Director and Audit Committee member of Certara Inc. (CERT) effective May 14, 2026. The resignation is not due to any disagreement with the company's operations, policies, or practices. This information was disclosed in an SEC Filing (8-K) on March 31, 2026.
Cynthia Collins to leave Certara (CERT) board and Audit Committee in May 2026
Certara, Inc. announced that board member Cynthia Collins will resign as a Class II director and a member of the Audit Committee, effective May 14, 2026, which coincides with the company's 2026 annual meeting of stockholders. The company stated that her decision is not due to any disagreement with Certara's operations, policies, or practices, indicating a planned governance change rather than a dispute. This upcoming change will create a vacancy on the Audit Committee that Certara will need to address.
Certara, Inc. $CERT Shares Acquired by Fort Washington Investment Advisors Inc. OH
Fort Washington Investment Advisors Inc. OH significantly increased its stake in Certara, Inc. (NASDAQ:CERT) by 133.4% in Q4 2025, bringing their total holdings to 2,272,823 shares valued at approximately $20.02 million. This increase makes them a notable institutional investor, holding about 1.43% of the company. Certara recently reported Q4 EPS of $0.09, missing estimates, with revenue slightly above expectations, and shares are currently trading near a one-year low.
Vanguard disaggregates holdings after realignment for Certara Inc (CERT)
The Vanguard Group filed an amendment to its Schedule 13G/A for Certara Inc (CERT), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately as per SEC guidance. The filing clarifies that Vanguard no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.
Certara (CERT) 10K Form and Latest SEC Filings 2026
This article provides an overview of Certara's (NASDAQ:CERT) SEC filings, highlighting that the company has submitted over 237 documents since 2020. It details the significance of various filing types like 10-K, 10-Q, and 8-K for investors, emphasizing their role as verified financial data sources. The most recent filing mentioned is a Form SCHEDULE 13G/A submitted on March 26, 2026, and the article also outlines Certara's typical 10-K filing schedule.
When Will Certara, Inc. (NASDAQ:CERT) Become Profitable?
Certara, Inc. (NASDAQ:CERT), a biosimulation software and services provider, is projected to achieve profitability in 2027, according to 13 industry analysts. The company posted a loss of US$1.6 million in 2025 but is expected to turn a profit of US$6.7 million in 2027, requiring a significant 72% year-on-year growth rate. Analysts express high confidence in this growth trajectory, noting the company's prudent capital management with low debt despite its current loss-making status.
Understanding Momentum Shifts in (CERT)
The article "Understanding Momentum Shifts in (CERT)" from Stock Traders Daily analyzes Certara Inc. (NASDAQ: CERT), indicating a weak sentiment across all horizons and a short bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for CERT.
If You Invested $1,000 in Certara, Inc. (CERT)
This article analyzes the performance of a $1,000 investment in Certara, Inc. (CERT) over various periods, showing significant negative returns. It also provides a detailed overview of Certara, Inc., describing its business as a software-focused company specializing in biosimulation for drug development, its key products, scientific orientation, and financial status. The company operates in the information sector, assisting biopharmaceutical companies and regulatory agencies globally.
CERT SEC Filings - Certara, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Certara, Inc. (CERT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event reports, along with insider trading information. It offers AI-powered summaries of these documents and real-time updates from EDGAR. Recent filings include disclosures of significant stakes by institutional investors Dimensional Fund Advisors LP and Wasatch Advisors LP, and an insider sale by Leif E. Pedersen.
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches
Certara (CERT) posted $418.8m in revenue and a small net loss in 2025, alongside FDA validation for its PBPK biosimulation platform. Despite this and new software launches, the stock has seen recent price pressure. While Simply Wall St's narrative suggests Certara is 30.8% undervalued with a fair value of $9.60, a market multiple comparison shows it trading at a premium to peers, indicating mixed signals for investors.
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches
Certara (CERT) is being re-evaluated by investors following US$418.8m revenue in 2025, a small net loss, and FDA validation for its PBPK modeling. Despite these positive developments and new software launches, the stock price has seen declines of 23.91% over 90 days and 39.10% over one year, indicating potential fading momentum. The article explores different valuation perspectives, including an estimated fair value of $9.60 per share from one narrative versus a market multiple that suggests less room for error due to a higher Price/Sales ratio compared to industry peers.
Certara, Inc. $CERT is ArrowMark Colorado Holdings LLC's 5th Largest Position
ArrowMark Colorado Holdings LLC recently reduced its stake in Certara, Inc. (NASDAQ:CERT) by 6.5% during the third quarter, though Certara remains its 5th largest holding, constituting 1.7% of its investment portfolio. Other institutional investors like First Horizon Corp and Versant Capital Management Inc. have either acquired new stakes or increased their positions in the company. Certara's stock shows a market capitalization of $1.06 billion, a negative P/E ratio, and recently missed earnings per share estimates, yet analysts still maintain a "Hold" consensus rating with an average target price of $11.10.
Topline Capital Management LLC Purchases Shares of 546,471 Certara, Inc. $CERT
Topline Capital Management LLC acquired 546,471 shares of Certara, Inc. (NASDAQ:CERT) in the third quarter, representing 1.1% of its portfolio. Certara reported Q3 earnings of $0.09 EPS, missing estimates, and revenue of $103.65 million, slightly exceeding expectations. The company, trading near a one-year low, has a consensus "Hold" rating with an average price target of $11.10 from analysts.
Alpha Wave Global LP Takes Position in Certara, Inc. $CERT
Alpha Wave Global LP recently acquired a significant new position in Certara, Inc. (NASDAQ:CERT) during the third quarter, purchasing over 500,000 shares valued at approximately $6.17 million. This investment makes Certara the 15th largest holding for Alpha Wave Global LP, representing about 0.6% of their portfolio. The article also reviews Certara's recent financial results, which included an EPS miss despite slightly exceeding revenue expectations, and provides an overview of the company's stock performance and current analyst ratings.
Avoiding Lag: Real-Time Signals in (CERT) Movement
This article analyzes Certara Inc. (NASDAQ: CERT) using AI models to provide real-time trading signals and strategies. It highlights near-term weak sentiment, tests of support levels, and offers detailed risk-reward setups for position, momentum, and risk hedging strategies. The analysis presents a multi-timeframe signal breakdown and emphasizes the exceptional 83.0:1 risk-reward setup targeting a 25.2% gain.
Certara at Barclays Healthcare Conference: Strategic Growth and AI Integration
Certara Inc. presented at the Barclays 28th Annual Global Healthcare Conference, highlighting strong 2025 performance with 7% organic software revenue growth and 32% adjusted EBITDA margin, despite anticipating a challenging Q1 2026. The company is strategically focused on model-informed drug development (MIDD), biosimulation, and integrating AI into its software platforms through new product launches like Certara IQ and Phoenix Cloud. Certara is also evaluating the future of its regulatory writing business, weighing its profitability against potential divestiture.
Dixon Mitchell Investment Counsel Inc. Purchases Shares of 866,380 Certara, Inc. $CERT
Dixon Mitchell Investment Counsel Inc. acquired a new stake of 866,380 shares of Certara, Inc. (NASDAQ:CERT) valued at approximately $10.59 million in Q3, representing 0.54% of the company. Institutional ownership of Certara is high at 73.96%, with significant increases from other funds like Wasatch Advisors LP and new positions from Fort Washington Investment Advisors Inc. Analysts currently have a "Hold" rating on Certara with an average price target of $11.10, despite the company recently missing quarterly EPS estimates.
How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials
Certara's Simcyp modeling tool has been accepted by the FDA to replace multiple clinical trials for a new drug application, reinforcing the company's core thesis in biosimulation. Despite this scientific milestone, Certara faces near-term pressure due to cautious pharma spending and modest revenue growth guidance, which has created a gap between its regulatory validation and commercial reality. Investors are keenly watching how this FDA acceptance translates into future bookings and sustained financial growth for the company over the long term.
Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of "Hold" from Brokerages
Certara, Inc. (NASDAQ:CERT) has received a consensus "Hold" rating from fourteen brokerages, with an average 12-month price target of $11.10. The company recently reported Q4 EPS of $0.09, missing consensus, and revenue of $103.65M, in line with expectations. Institutional investors own approximately 73.96% of the stock.
Certara at Leerink Conference: Strategic Moves Amid Challenges
Certara Inc. (NASDAQ:CERT) presented at the Leerink Global Healthcare Conference 2026, discussing its performance and strategies. Despite meeting Q4 revenue and EBITDA expectations, the company faced challenges in software bookings, leading to a projected 0% to 4% revenue growth for 2026. With a new CEO, Jon Resnick, Certara plans to enhance commercial execution, customer focus, and invest in AI and biosimulation, while also considering M&A and share repurchases.
How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials
Certara's Simcyp biosimulation platform recently received FDA acceptance to replace multiple clinical pharmacology studies for asciminib, a significant scientific milestone. While this validates biosimulation's role in drug development, investors are noting a contrast with the company's modest 2026 revenue guidance of 0% to 4% growth. This suggests that the translation of scientific wins into accelerated revenue growth might take longer due to cautious pharma spending and the timing of bookings and broader software adoption.
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And Latest Earnings Guidance
Certara's share price has seen a significant decline despite its physiologically based pharmacokinetic (PBPK) modeling recently being accepted by the FDA for a cancer drug's new drug application. While a popular valuation narrative suggests Certara is undervalued at $12.38 per share compared to its current $7.06, its Price-to-Sales ratio of 2.7x is higher than the industry average, pointing to a potential overvaluation when considering sales performance. The company's future hinges on the adoption of its AI-enabled platforms and managing potential risks like slow pharma adoption and rising costs.
Certara appoints Jon Resnick as new CEO; reaffirms FY25 outlook
Certara has announced the appointment of Jon Resnick as its new Chief Executive Officer, effective December 2, 2024. Resnick, who previously served as CEO of Paradigm Diagnostics and held leadership roles at Roche and Genentech, succeeds William Feehery. The company also reaffirmed its financial outlook for fiscal year 2025.
CERT - Certara Inc Stock Price and Quote
This article provides comprehensive stock information for Certara Inc. (CERT), including its current stock price, financial metrics, analyst ratings, and recent news. It highlights the company's performance, insider transactions, and its involvement in advancing drug development through technology and AI.
Forecasting The Future: 7 Analyst Projections For Certara
This article analyzes recent analyst ratings and projections for Certara (NASDAQ: CERT). Over the past three months, 7 analysts have provided ratings, with an average 12-month price target of $11.14, reflecting a decrease from the previous average. The report also details Certara's financial performance, including its revenue growth, net margin, return on equity, return on assets, and debt management, highlighting its strong profitability and effective asset utilization.
Certara (CERT) Downgraded to Equal-Weight by Barclays | CERT Stock News
Barclays has downgraded Certara (CERT) from "Overweight" to "Equal-Weight," while maintaining a price target of $8.00. This adjustment came on March 6, 2026, and follows several other recent analyst rating changes for Certara. Despite the downgrade, the average analyst target price suggests a significant upside from its current price, and GuruFocus estimates a fair value of $16.12 for the stock.
Certara, Inc. (CERT): Analysts Assign Equal-Weight Rating Amid Price Stagnation
Barclays has assigned an Equal-Weight rating to Certara, Inc. (NASDAQ: CERT), setting a price target of $8.00 while the stock currently trades at $7.24. This rating comes amidst recent price stagnation, moderate volatility, and a significant miss in its latest earnings report. Despite a mixed performance history and a ST Score of 53, analysts maintain a generally positive outlook with five Buy and two Hold ratings, suggesting long-term potential for the biotech analytics company.
Forecasting The Future: 7 Analyst Projections For Certara
Seven analysts have provided ratings for Certara (NASDAQ: CERT) over the past three months, with most holding a "Somewhat Bullish" stance. The average 12-month price target is $11.14, a 15.41% decrease from the previous average. Certara's financial highlights include positive revenue growth of 10.33%, a strong net margin of 1.46%, and impressive returns on equity and assets, while maintaining a balanced debt-to-equity ratio.
Certara's (CERT) Equal Weight Rating Reiterated at Barclays
Barclays has reiterated an "Equal Weight" rating for Certara (NASDAQ:CERT) with an $8.00 price target, suggesting an 11.9% upside. This comes after Certara reported adjusted earnings per share of $0.09, missing estimates, and revenue of $103.65 million, which was largely in line. The consensus among analysts remains a "Hold" with an average target price of $11.10.
Certara (CERT) Downgraded to Equal-Weight by Barclays | CERT Stock News
Barclays has downgraded Certara (CERT) from an "Overweight" to an "Equal-Weight" rating while maintaining its price target at $8.00. This adjustment reflects an updated perspective on the company's performance and market conditions. Despite the downgrade, other analysts have a consensus "Outperform" status for Certara with an average target price of $9.98, implying a 39.47% upside from its current price, while GuruFocus estimates a fair value suggesting a 125.3% upside.
Barclays downgrades Certara stock rating on turnaround concerns
Barclays has downgraded Certara Inc. (NASDAQ:CERT) to Equalweight from Overweight, setting an $8.00 price target due to concerns about the extent of investment needed for the company's turnaround and potential impacts on margins. Analyst Luke Sergott noted that the business requires more significant investment across its organization to accelerate core growth than initially expected, making a durable valuation unlock some time away. This comes after Certara reported mixed Q4 2025 earnings and faced other analyst downgrades and price target reductions from Craig-Hallum, TD Cowen, and Leerink Partners.
Certara Simcyp Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Certara announced that its Simcyp® Simulator's physiologically-based pharmacokinetic (PBPK) modeling predictions were accepted by the U.S. FDA, replacing ten human trials to support the new drug application for asciminib (Scemblix®) for Chronic Myeloid Leukemia. This highlights how model-informed drug development, using virtual biological systems, can save time and money in drug development and regulatory decision-making. The Simcyp Simulator provided a mechanistic assessment of asciminib’s pharmacokinetics, complementing and replacing clinical pharmacology studies in the NDA.
FDA accepts virtual-patient data so leukemia drug avoids 10 trials
Certara announced that the U.S. FDA accepted its Simcyp® Simulator PBPK modeling for the new drug application (NDA) of asciminib (Scemblix) for chronic myeloid leukemia. This virtual patient data replaced at least ten human clinical pharmacology studies, saving significant time and cost in drug development. The move highlights the increasing regulatory acceptance of biosimulation in drug development and its practical benefits.
Certara Earnings Call: Software Strength Amid Transition
Certara's earnings call highlighted a mixed performance with solid full-year revenue growth and strong software sales, but disappointing Q4 profitability and software bookings. The company views 2026 as a transition year, focusing on new CEO strategies, AI integration, and addressing execution challenges to convert its strong bookings base into sustained growth. Despite short-term pressures, Certara remains fundamentally profitable with good cash reserves and a commitment to capital returns.
Certara (CERT) director granted 5,547 restricted stock units
Certara, Inc. director Arjun Bedi was granted 5,547 restricted stock units (RSUs) on February 27, 2026, as part of the company's 2020 Incentive Plan. Each RSU represents one share of common stock and will vest on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting. This grant is part of Bedi's equity-based compensation and aims to align his interests with shareholders.
Certara (CERT) Is Up 9.6% After Calling 2026 a Transition Year With Slower Growth Guidance
Certara (CERT) stock rose 9.6% after the company declared 2026 a "transition year" with a revenue growth forecast of 0%-4%. In Q4 2025, Certara's revenue increased to US$103.65 million from US$100.36 million a year prior, but it shifted from a net income to a net loss of US$5.9 million. The company is focusing on cost discipline, AI-enabled product launches, and a potential strategic review of its regulatory writing business, while analysts have lowered their expectations.
Certara, Inc. Hits 52-Week Low at USD 6.04 Amid Market Struggles
Certara, Inc. (CRTRA) has reached a new 52-week low of USD 6.04, signifying a 36.27% stock price decline over the past year. The small-cap software company has a market capitalization of USD 1,029 million, a high price-to-earnings ratio of 173.00, and a low return on equity of 1.20%. This performance highlights the volatility inherent in the small-cap software sector.
